Company / Cash & Equivalents
Ventyx Biosciences, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$27.3M
FY2024
5-year range
$244.0K / $70.8M
FY2020-FY2024
Trend
-47.1%
vs FY2023
Sector context
#197 of 208
Health Care
What the data says
Among 208 Health Care companies, Ventyx Biosciences, Inc. is in the bottom 5% for cash & equivalents. Cash & Equivalents has declined for 3 consecutive years, from $71M in FY2021 to $27M in FY2024.
Based on SEC 10-K filings.
$27M in FY2024 with a 3-year CAGR of -27.2%.
Declined from $65M to $27M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -27.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 208This company $27.3M Sector average $694.3M
▼
-96.1% below sector average
Key checks
Key Insights
- Ventyx Biosciences, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -27.2%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 47.1% year-over-year.
- Ranks #197 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $27.3M | -47.1% |
| FY2023 | $51.6M | -20.4% |
| FY2022 | $64.8M | -8.4% |
| FY2021 | $70.8M | +28912.7% |
| FY2020 | $244.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026